DE1795438C2 - S.S-Diamino-o-chlor pyrazincarbonsäuremethylester und Verfahren zu dessen Herstellung. Ausscheidung aus: 1470053 - Google Patents

S.S-Diamino-o-chlor pyrazincarbonsäuremethylester und Verfahren zu dessen Herstellung. Ausscheidung aus: 1470053

Info

Publication number
DE1795438C2
DE1795438C2 DE1795438A DE1795438DA DE1795438C2 DE 1795438 C2 DE1795438 C2 DE 1795438C2 DE 1795438 A DE1795438 A DE 1795438A DE 1795438D A DE1795438D A DE 1795438DA DE 1795438 C2 DE1795438 C2 DE 1795438C2
Authority
DE
Germany
Prior art keywords
diamino
preparation
acid methyl
chloropyrazine
elimination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE1795438A
Other languages
German (de)
English (en)
Other versions
DE1795438B1 (de
Inventor
Edward Jethro Lansdale R.D. Pa. Cragoejun. (V.St.A.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of DE1795438B1 publication Critical patent/DE1795438B1/de
Application granted granted Critical
Publication of DE1795438C2 publication Critical patent/DE1795438C2/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE1795438A 1962-10-30 1963-10-28 S.S-Diamino-o-chlor pyrazincarbonsäuremethylester und Verfahren zu dessen Herstellung. Ausscheidung aus: 1470053 Expired DE1795438C2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23423062A 1962-10-30 1962-10-30
US313315A US3313813A (en) 1962-10-30 1963-10-07 (3-amino-5, 6-disubstituted-pyrazinoyl) guanidines

Publications (2)

Publication Number Publication Date
DE1795438B1 DE1795438B1 (de) 1973-09-06
DE1795438C2 true DE1795438C2 (de) 1974-04-11

Family

ID=26927694

Family Applications (2)

Application Number Title Priority Date Filing Date
DE1795438A Expired DE1795438C2 (de) 1962-10-30 1963-10-28 S.S-Diamino-o-chlor pyrazincarbonsäuremethylester und Verfahren zu dessen Herstellung. Ausscheidung aus: 1470053
DE19631470053 Pending DE1470053A1 (de) 1962-10-30 1963-10-28 5,6-disubstituierte (3-Aminopyrazinoyl)-guanidinverbindungen und Verfahren zu deren Herstellung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE19631470053 Pending DE1470053A1 (de) 1962-10-30 1963-10-28 5,6-disubstituierte (3-Aminopyrazinoyl)-guanidinverbindungen und Verfahren zu deren Herstellung

Country Status (13)

Country Link
US (1) US3313813A (OSRAM)
BE (1) BE639386A (OSRAM)
BR (1) BR6354164D0 (OSRAM)
CH (1) CH465617A (OSRAM)
CY (1) CY440A (OSRAM)
DE (2) DE1795438C2 (OSRAM)
DK (4) DK114978B (OSRAM)
FI (1) FI47102C (OSRAM)
FR (1) FR1563612A (OSRAM)
GB (1) GB1066855A (OSRAM)
MY (1) MY6900026A (OSRAM)
NL (2) NL142413B (OSRAM)
SE (1) SE321230B (OSRAM)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6409714A (OSRAM) * 1962-10-30 1965-10-01
US3472848A (en) * 1966-11-17 1969-10-14 Merck & Co Inc 3-hydroxy and 3-mercapto-pyrazinoyl-guanidines,corresponding ethers and thioethers and processes for their preparation
US3948895A (en) * 1971-09-28 1976-04-06 E. I. Du Pont De Nemours And Company Synthesis of 3,5-diaminopyrazinoic acid from 3,5-diamino-2,6-dicyanopyrazine and intermediates
US4085211A (en) * 1975-12-15 1978-04-18 Merck & Co., Inc. Pyrazinecarboxamides and processes for preparing same
US4087526A (en) * 1976-07-23 1978-05-02 Merck & Co., Inc. (3-Amino-5-substituted-6-fluoropyrazinoyl or pyrazamido)-guanidines and their derivatives bearing substituents on the guanidino nitrogens
US4208413A (en) * 1977-03-04 1980-06-17 Merck & Co., Inc. N-Pyrazinecarbonyl-N'-alkoxycarbonyl and N',N"-bis(alkoxycarbonyl)guanidines and processes for preparing same
US4108859A (en) * 1977-06-06 1978-08-22 The Dow Chemical Company Microbicidal (pyridinylamino) alkyl guanidines
US4140776A (en) * 1977-09-16 1979-02-20 Merck & Co., Inc. N-pyrazinecarbonyl-N'-acylguanidines
US4190655A (en) * 1978-08-28 1980-02-26 Merck & Co., Inc. Amiloride citrate
EP0009054A1 (en) * 1978-09-19 1980-04-02 Merck & Co. Inc. N-Pyrazinecarbonyl-N'-substituted-sulfamoyl-guanidine and processes for preparing same
US4224447A (en) * 1979-03-27 1980-09-23 Merck & Co., Inc. Novel pyrazinecarboxamides and processes for preparing same
US4246406A (en) * 1979-03-27 1981-01-20 Merck & Co., Inc. Heterocyclic substituted pyrazinoylguanidines
US4309540A (en) * 1980-05-19 1982-01-05 Merck & Co., Inc. Substituted pyrazinyl-1,2,4-oxadiazoles
US4362724A (en) * 1980-05-19 1982-12-07 Merck & Co., Inc. Method of treating edema and hypertension and pharmaceutical composition therefor in which the active ingredient comprises a novel substituted pyrazinyl-1,2,4-oxadiazole and a kaliuretic diuretic
US4454132A (en) * 1981-03-16 1984-06-12 Merck & Co., Inc. Pharmaceutical compositions of novel substituted pyrazinyl-1,2,4-oxadiazoles useful in the treatment of edema and hypertension
US4510322A (en) * 1981-07-13 1985-04-09 Merck & Co., Inc. Indacrinone having enhanced uricosuric
US4952582A (en) * 1982-01-04 1990-08-28 Beyer Jr Karl H Pyrazinoylguanidine and derivatives thereof having few polar substituents and being useful as hyperuretic agents
US4663322A (en) * 1982-01-04 1987-05-05 Beyer Jr Karl H Antihypertensive hyperuretic and saluretic agent combinations
DE3312516A1 (de) * 1983-04-07 1984-10-11 Brigitte Dr. 7400 Tübingen Pfeiffer Kernsubstituierte phenylalkylenguanidinderivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
US4604394A (en) * 1984-10-01 1986-08-05 Merck & Co., Inc. Antiarrhythmic compositions and method
DE3925847A1 (de) * 1989-08-04 1991-02-07 Huels Chemische Werke Ag Verfahren zur herstellung von 3-aminopyrazin-2-carbonsaeuremethylester
US5304125A (en) * 1990-10-05 1994-04-19 The University Of North Carolina Apparatus for administering solid particulate aerosols to the lungs
EP0551445A4 (en) * 1990-10-05 1994-05-11 Univ North Carolina Method of administering amiloride
TW213903B (OSRAM) * 1991-08-16 1993-10-01 Boehringer Ingelheim Kg
US6169107B1 (en) 1993-04-28 2001-01-02 Sumitomo Pharmaceutical Co., Ltd. Indoloylguanidine derivatives
DE4337609A1 (de) * 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Pyrazincarboxamidderivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
US5656256A (en) * 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
TW372967B (en) * 1994-12-27 1999-11-01 Kanebo Ltd 1,4 benzoxazine derivative, pharmaceutical composition containing the same and use thereof
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5628984A (en) * 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
US5801177A (en) * 1995-12-14 1998-09-01 Beyer, Jr.; Karl H. Method for controlling and/or lowering serum glucose and fatty acid concentrations and hypertensive blood pressure in non-insulin-dependent diabetic patients
US5877217A (en) * 1995-12-26 1999-03-02 Alteon Inc. N-acylaminoalkyl-hydrazinecarboximidamides
BR9811612A (pt) * 1997-08-29 2000-08-08 Univ North Carolina Uso de 5' -difosfato de uridina e similares para tratamento de doenças pulmonares
ATE347880T1 (de) * 1998-10-20 2007-01-15 Univ North Carolina Methoden zum befeuchten der nasenschleimhaut
CA2360687A1 (en) * 1999-01-29 2000-08-03 Karl H. Beyer, Jr. (Deceased) Composition and method for treating diabetes
CA2378181A1 (en) 1999-07-19 2001-01-25 Richard C. Boucher, Jr. Conjugates of sodium channel blockers and methods of using the same
PT1336407E (pt) 2000-11-21 2006-07-31 Sankyo Co Composicao contendo um antagonista do receptor de angiotensina e um diuretico e sua utilizacao para o tratamento da hipertensao
US6858615B2 (en) * 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US6858614B2 (en) * 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenolic guanidine sodium channel blockers
US7704995B2 (en) * 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
WO2003093297A2 (en) * 2002-05-03 2003-11-13 Exelixis, Inc. Protein kinase modulators and methods of use
EP1545519B1 (en) 2002-08-19 2011-03-23 Pfizer Inc. Combination therapy for hyperproliferative diseases
US6903105B2 (en) * 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
BRPI0411900B8 (pt) 2003-06-26 2021-05-25 Biotron Ltd compostos e composições farmacêuticas compreendendo os mesmos
AU2004248859C1 (en) * 2003-06-26 2011-11-24 Biotron Limited Antiviral acylguanidine compounds and methods
US7326706B2 (en) * 2003-08-15 2008-02-05 Bristol-Myers Squibb Company Pyrazine modulators of cannabinoid receptors
US7064129B2 (en) * 2003-08-18 2006-06-20 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
JP2007502827A (ja) * 2003-08-18 2007-02-15 パリオン・サイエンシィズ・インコーポレーテッド 脂肪族ピラジノイルグアニジンナトリウムチャネルブロッカー
US20050090505A1 (en) * 2003-08-18 2005-04-28 Johnson Michael R. Methods of reducing risk of infection from pathogens
US20090253714A1 (en) * 2003-08-20 2009-10-08 Johnson Michael R Methods of reducing risk of infection from pathogens
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US20070099968A1 (en) * 2004-06-26 2007-05-03 Biotron Limited Antiviral compounds and methods
US20070021439A1 (en) * 2005-07-25 2007-01-25 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
WO2007062222A2 (en) * 2005-11-22 2007-05-31 University Of South Florida Inhibition of cell proliferation
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
EP2094643B1 (en) 2006-12-01 2012-02-29 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
WO2009049159A1 (en) 2007-10-10 2009-04-16 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
BRPI0907823A2 (pt) * 2008-02-26 2015-07-21 Parion Sciences Inc Bloqueadores poliaromáticos dos canais de sódio
DE102008053024B4 (de) 2008-10-24 2015-04-30 RUHR-UNIVERSITäT BOCHUM Verwendung von Amilorid-Derivaten zur Bekämpfung von Insekten und Milben
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
WO2013003444A1 (en) 2011-06-27 2013-01-03 Michael Ross Johnson A chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
SI2855435T1 (sl) 2012-05-29 2018-09-28 Parion Sciences Inc. Dendrimeru podobni amino amidi, ki imajo delovanje blokatorja natrijevih kanalov za zdravljenje suhih oči in drugih mukoznih bolezni
AU2013363215B2 (en) 2012-12-17 2018-03-01 Parion Sciences, Inc. 3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
CA2895512C (en) 2012-12-17 2021-10-19 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
KR101695582B1 (ko) 2013-04-17 2017-01-13 화이자 인코포레이티드 심혈관 질환을 치료하기 위한 n-피페리딘-3-일벤즈아미드 유도체
EP3019492B1 (en) * 2013-07-08 2017-09-06 Boehringer Ingelheim International GmbH Amiloride-type compounds as inhibitors in epithelial sodium channels for the treatment of diseases of the lungs and airways
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
WO2018021520A1 (ja) 2016-07-29 2018-02-01 東レ株式会社 グアニジン誘導体及びその医薬用途
CN119060040A (zh) 2019-01-18 2024-12-03 阿斯利康(瑞典)有限公司 Pcsk9抑制剂及其使用方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE639393A (OSRAM) * 1962-10-30

Also Published As

Publication number Publication date
DK115403B (da) 1969-10-06
NL142413B (nl) 1974-06-17
US3313813A (en) 1967-04-11
DK116943B (da) 1970-03-02
NL299931A (OSRAM)
BE639386A (OSRAM)
DK114978B (da) 1969-08-25
BR6354164D0 (pt) 1973-09-18
CY440A (en) 1968-05-18
SE321230B (OSRAM) 1970-03-02
FI47102C (fi) 1973-09-10
CH465617A (de) 1968-11-30
FI47102B (OSRAM) 1973-05-31
MY6900026A (en) 1969-12-31
GB1066855A (en) 1967-04-26
FR1563612A (OSRAM) 1969-04-18
DE1470053A1 (de) 1969-06-26
DK114557B (da) 1969-07-14
DE1795438B1 (de) 1973-09-06

Similar Documents

Publication Publication Date Title
DE1795438C2 (de) S.S-Diamino-o-chlor pyrazincarbonsäuremethylester und Verfahren zu dessen Herstellung. Ausscheidung aus: 1470053
ATE28386T1 (de) Verfahren zur herstellung und waermebehandlung von nahrungsmitteln und vorrichtung zur durchfuehrung desselben.
ES282416A1 (es) Procedimiento para la preparación de mezclas de ésteres de sucrosa
FR1264772A (fr) Procédé de préparation d'esters de l'acide acéto-acétique
CH388301A (de) Verfahren zur Herstellung von 2,5-diarylamino-3,6-dihydro-terephthalsäureestern
GB1081091A (en) Improvements in or relating to the preparation of dinitrotoluenes
CH388955A (de) Verfahren zur Herstellung von Dithiophosphonsäureester-amiden
CH423755A (de) Verfahren zur Herstellung von Hexen-(3)-säure-hexen-(3)-yl-ester
FR1303225A (fr) Procédé de préparation de l'acide l-glutamique et de l'acide alpha-cétoglutarique
DE868903C (de) Verfahren zur Herstellung von Pyromellithsaeure aus Koks
SU145565A1 (ru) Способ получени дихлорацетамида
DE950466C (de) Verfahren zur Herstellung von Acylaminocarbonsaeureestern
DE589545C (de) Verfahren zur Herstellung von Acetylcellulose
SU367147A1 (ru) Всесоюзная iб>&'&л''''о" '1иа
DE902009C (de) Verfahren zur Herstellung von schwefelhaltigen Verbindungen
GB793926A (en) Improvements relating to the preparation of dialkyl esters of terephthalic acid
DE1036856B (de) Verfahren zur Herstellung von Dilactamen
AT208839B (de) Verfahren zur Herstellung von L-(+)-Glutamin
GB1104779A (en) Process for preparing methacrylamide sulphate
SU455969A1 (ru) Способ получени алкиловых эфиров диалкоксифосфинилацетоуксусных кислот
GB907126A (en) Improvements in or relating to terephthalic acid
GB971570A (en) A process for preparing alpha,beta-unsaturated carboxylic acids
GB844237A (en) Esters of aromatic dicarboxylic acids
ATE2425T1 (de) Verfahren zur herstellung von n,n'diacetylethylendiamin.
DE1053486B (de) Verfahren zur Herstellung von gemischten Anhydriden aus Dicarbonsaeuren und teilveresterter antimoniger Saeure

Legal Events

Date Code Title Description
E77 Valid patent as to the heymanns-index 1977